Otsuka Holdings Co., Ltd. – Unsponsored ADR (OTCMKTS:OTSKY – Get Free Report) hit a new 52-week high on Monday . The company traded as high as $30.60 and last traded at $30.53, with a volume of 2094 shares traded. The stock had previously closed at $30.0950.
Analysts Set New Price Targets
Several analysts have commented on the company. Morgan Stanley upgraded Otsuka to an “overweight” rating in a research note on Friday. Zacks Research raised Otsuka from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, December 9th. One equities research analyst has rated the stock with a Strong Buy rating and one has given a Buy rating to the company’s stock. According to MarketBeat.com, Otsuka has a consensus rating of “Strong Buy”.
View Our Latest Analysis on OTSKY
Otsuka Stock Performance
About Otsuka
Otsuka Pharmaceutical Co, Ltd., trading in the U.S. under the ticker OTCMKTS:OTSKY, is a global healthcare company headquartered in Tokyo, Japan. The firm’s core activities span the development, manufacturing and marketing of prescription pharmaceuticals, consumer healthcare products and nutraceuticals. Otsuka focuses its research on areas such as neuroscience, cardiovascular and renal therapies, and oncology, aiming to bring innovative treatments to patients worldwide.
Founded in 1964 by Busaburo Otsuka as a subsidiary of the Otsuka Group, the company has grown into a diversified healthcare enterprise over more than five decades.
See Also
- Five stocks we like better than Otsuka
- Your Signature Is Missing – Act Before It’s Too Late
- What Expenses Can Be Deducted From Capital Gains Tax?
- A month before the crash
- The $100 Trillion AI Story No One Is Telling You
- Refund From 1933: Trump’s Reset May Create Instant Wealth
Receive News & Ratings for Otsuka Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Otsuka and related companies with MarketBeat.com's FREE daily email newsletter.
